APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immuno-oncology Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Immuno-oncology Drugs Market Analysis and Forecast 2026-2032

22 December 2025215 pages

Choose your research edition.

Industry ResearchImmuno-oncology Drugs Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Immuno-oncology Drugs Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Immuno-oncology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immuno-oncology Drugs Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Immuno-oncology Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Immuno-oncology Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Immuno-oncology Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Immuno-oncology Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Immuno-oncology Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Immuno-oncology Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Immuno-oncology Drugs include Sanofi S.A., Johnson & Johnson, Merck & Co., Lonza Group, Eli Lilly and Company, Pfizer Inc., Ferring Pharmaceuticals, Amgen, Inc and AbbVie, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Immuno-oncology Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Immuno-oncology Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Immuno-oncology Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Immuno-oncology Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Immuno-oncology Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Immuno-oncology Drugs revenue, projected growth trends, production technology, application and end-user industry.

Immuno-oncology Drugs Segment by Company

Sanofi S.A.

Johnson & Johnson

Merck & Co.

Lonza Group

Eli Lilly and Company

Pfizer Inc.

Ferring Pharmaceuticals

Amgen, Inc

AbbVie, Inc.

AstraZeneca, Plc

Spring Bank Pharmaceuticals, Inc.

Prometheus Therapeutics & Diagnostics

Novartis International AG

Incyte

ImmunoCellular Therapeutics

Hoffmann-La Roche AG

Gilead Sciences Inc.

Galena Biopharma

Enzo Biochem, Inc.

EMD Serono, Inc.

Dendreon Corporation

Celldex Therapeutics

Celgene Corporation

Bristol-Myers Squibb

Bio-Rad Laboratories, Inc.

Bavarian Nordic

Avantor, Inc.

Agilent Technologies Inc.

Agenus Inc.

Aduro BioTech

Immuno-oncology Drugs Segment by Type

Oncolytic Virus

Immune System Modulators

Immune Checkpoint Inhibitors

Cancer Vaccines

Others

Immuno-oncology Drugs Segment by Application

Clinics

Hospitals

Community Centers

Immuno-oncology Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immuno-oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-oncology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Immuno-oncology Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Immuno-oncology Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immuno-oncology Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Immuno-oncology Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oncolytic Virus Major Player Table 3. Immune System Modulators Major Player Table 4. Immune Checkpoint Inhibitors Major Player Table 5. Cancer Vaccines Major Player Table 6. Others Major Player Table 7. Global Immuno-oncology Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Clinics Major Player Table 9. Hospitals Major Player Table 10. Community Centers Major Player Table 11. Immuno-oncology Drugs Industry Trends Table 12. Immuno-oncology Drugs Industry Drivers Table 13. Immuno-oncology Drugs Industry Opportunities and Challenges Table 14. Immuno-oncology Drugs Industry Restraints Table 15. Global Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Immuno-oncology Drugs Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Immuno-oncology Drugs Market Share by Region (2021-2026) Table 18. Global Immuno-oncology Drugs Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Immuno-oncology Drugs Market Share by Region (2027-2032) Table 20. Global Immuno-oncology Drugs Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Immuno-oncology Drugs Revenue Market Share by Players (2021-2026) Table 22. Global Immuno-oncology Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Immuno-oncology Drugs Key Players Headquarters & Area Served Table 24. Global Immuno-oncology Drugs Players, Product Type & Application Table 25. Global Immuno-oncology Drugs Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Immuno-oncology Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Immuno-oncology Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Immuno-oncology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Immuno-oncology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Immuno-oncology Drugs Revenue Market Share by Type (2021-2026) Table 32. Global Immuno-oncology Drugs Revenue Market Share by Type (2027-2032) Table 33. Global Immuno-oncology Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Immuno-oncology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Immuno-oncology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Immuno-oncology Drugs Revenue Market Share by Application (2021-2026) Table 37. Global Immuno-oncology Drugs Revenue Market Share by Application (2027-2032) Table 38. Sanofi S.A. Company Information Table 39. Sanofi S.A. Business Overview Table 40. Sanofi S.A. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Sanofi S.A. Immuno-oncology Drugs Product Portfolio Table 42. Sanofi S.A. Recent Development Table 43. Johnson & Johnson Company Information Table 44. Johnson & Johnson Business Overview Table 45. Johnson & Johnson Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Johnson & Johnson Immuno-oncology Drugs Product Portfolio Table 47. Johnson & Johnson Recent Development Table 48. Merck & Co. Company Information Table 49. Merck & Co. Business Overview Table 50. Merck & Co. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Merck & Co. Immuno-oncology Drugs Product Portfolio Table 52. Merck & Co. Recent Development Table 53. Lonza Group Company Information Table 54. Lonza Group Business Overview Table 55. Lonza Group Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Lonza Group Immuno-oncology Drugs Product Portfolio Table 57. Lonza Group Recent Development Table 58. Eli Lilly and Company Company Information Table 59. Eli Lilly and Company Business Overview Table 60. Eli Lilly and Company Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Eli Lilly and Company Immuno-oncology Drugs Product Portfolio Table 62. Eli Lilly and Company Recent Development Table 63. Pfizer Inc. Company Information Table 64. Pfizer Inc. Business Overview Table 65. Pfizer Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Pfizer Inc. Immuno-oncology Drugs Product Portfolio Table 67. Pfizer Inc. Recent Development Table 68. Ferring Pharmaceuticals Company Information Table 69. Ferring Pharmaceuticals Business Overview Table 70. Ferring Pharmaceuticals Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolio Table 72. Ferring Pharmaceuticals Recent Development Table 73. Amgen, Inc Company Information Table 74. Amgen, Inc Business Overview Table 75. Amgen, Inc Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Amgen, Inc Immuno-oncology Drugs Product Portfolio Table 77. Amgen, Inc Recent Development Table 78. AbbVie, Inc. Company Information Table 79. AbbVie, Inc. Business Overview Table 80. AbbVie, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. AbbVie, Inc. Immuno-oncology Drugs Product Portfolio Table 82. AbbVie, Inc. Recent Development Table 83. AstraZeneca, Plc Company Information Table 84. AstraZeneca, Plc Business Overview Table 85. AstraZeneca, Plc Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio Table 87. AstraZeneca, Plc Recent Development Table 88. Spring Bank Pharmaceuticals, Inc. Company Information Table 89. Spring Bank Pharmaceuticals, Inc. Business Overview Table 90. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolio Table 92. Spring Bank Pharmaceuticals, Inc. Recent Development Table 93. Prometheus Therapeutics & Diagnostics Company Information Table 94. Prometheus Therapeutics & Diagnostics Business Overview Table 95. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio Table 97. Prometheus Therapeutics & Diagnostics Recent Development Table 98. Novartis International AG Company Information Table 99. Novartis International AG Business Overview Table 100. Novartis International AG Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Novartis International AG Immuno-oncology Drugs Product Portfolio Table 102. Novartis International AG Recent Development Table 103. Incyte Company Information Table 104. Incyte Business Overview Table 105. Incyte Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Incyte Immuno-oncology Drugs Product Portfolio Table 107. Incyte Recent Development Table 108. ImmunoCellular Therapeutics Company Information Table 109. ImmunoCellular Therapeutics Business Overview Table 110. ImmunoCellular Therapeutics Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio Table 112. ImmunoCellular Therapeutics Recent Development Table 113. Hoffmann-La Roche AG Company Information Table 114. Hoffmann-La Roche AG Business Overview Table 115. Hoffmann-La Roche AG Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio Table 117. Hoffmann-La Roche AG Recent Development Table 118. Gilead Sciences Inc. Company Information Table 119. Gilead Sciences Inc. Business Overview Table 120. Gilead Sciences Inc. Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolio Table 122. Gilead Sciences Inc. Recent Development Table 123. Galena Biopharma Company Information Table 124. Galena Biopharma Business Overview Table 125. Galena Biopharma Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Galena Biopharma Immuno-oncology Drugs Product Portfolio Table 127. Galena Biopharma Recent Development Table 128. Enzo Biochem, Inc. Company Information Table 129. Enzo Biochem, Inc. Business Overview Table 130. Enzo Biochem, Inc. Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolio Table 132. Enzo Biochem, Inc. Recent Development Table 133. EMD Serono, Inc. Company Information Table 134. EMD Serono, Inc. Business Overview Table 135. EMD Serono, Inc. Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. EMD Serono, Inc. Immuno-oncology Drugs Product Portfolio Table 137. EMD Serono, Inc. Recent Development Table 138. Dendreon Corporation Company Information Table 139. Dendreon Corporation Business Overview Table 140. Dendreon Corporation Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Dendreon Corporation Immuno-oncology Drugs Product Portfolio Table 142. Dendreon Corporation Recent Development Table 143. Celldex Therapeutics Company Information Table 144. Celldex Therapeutics Business Overview Table 145. Celldex Therapeutics Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 146. Celldex Therapeutics Immuno-oncology Drugs Product Portfolio Table 147. Celldex Therapeutics Recent Development Table 148. Celgene Corporation Company Information Table 149. Celgene Corporation Business Overview Table 150. Celgene Corporation Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 151. Celgene Corporation Immuno-oncology Drugs Product Portfolio Table 152. Celgene Corporation Recent Development Table 153. Bristol-Myers Squibb Company Information Table 154. Bristol-Myers Squibb Business Overview Table 155. Bristol-Myers Squibb Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 156. Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio Table 157. Bristol-Myers Squibb Recent Development Table 158. Bio-Rad Laboratories, Inc. Company Information Table 159. Bio-Rad Laboratories, Inc. Business Overview Table 160. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 161. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolio Table 162. Bio-Rad Laboratories, Inc. Recent Development Table 163. Bavarian Nordic Company Information Table 164. Bavarian Nordic Business Overview Table 165. Bavarian Nordic Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 166. Bavarian Nordic Immuno-oncology Drugs Product Portfolio Table 167. Bavarian Nordic Recent Development Table 168. Avantor, Inc. Company Information Table 169. Avantor, Inc. Business Overview Table 170. Avantor, Inc. Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 171. Avantor, Inc. Immuno-oncology Drugs Product Portfolio Table 172. Avantor, Inc. Recent Development Table 173. Agilent Technologies Inc. Company Information Table 174. Agilent Technologies Inc. Business Overview Table 175. Agilent Technologies Inc. Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 176. Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolio Table 177. Agilent Technologies Inc. Recent Development Table 178. Agenus Inc. Company Information Table 179. Agenus Inc. Business Overview Table 180. Agenus Inc. Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 181. Agenus Inc. Immuno-oncology Drugs Product Portfolio Table 182. Agenus Inc. Recent Development Table 183. Aduro BioTech Company Information Table 184. Aduro BioTech Business Overview Table 185. Aduro BioTech Immuno-oncology Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 186. Aduro BioTech Immuno-oncology Drugs Product Portfolio Table 187. Aduro BioTech Recent Development Table 188. North America Immuno-oncology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 189. North America Immuno-oncology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 190. North America Immuno-oncology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 191. North America Immuno-oncology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 192. North America Immuno-oncology Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 193. North America Immuno-oncology Drugs Revenue by Country (2021-2026) & (US$ Million) Table 194. North America Immuno-oncology Drugs Revenue by Country (US$ Million) & (2027-2032) Table 195. Europe Immuno-oncology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 196. Europe Immuno-oncology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 197. Europe Immuno-oncology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 198. Europe Immuno-oncology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 199. Europe Immuno-oncology Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 200. Europe Immuno-oncology Drugs Revenue by Country (2021-2026) & (US$ Million) Table 201. Europe Immuno-oncology Drugs Revenue by Country (US$ Million) & (2027-2032) Table 202. China Immuno-oncology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 203. China Immuno-oncology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 204. China Immuno-oncology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 205. China Immuno-oncology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 206. Asia Immuno-oncology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 207. Asia Immuno-oncology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 208. Asia Immuno-oncology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 209. Asia Immuno-oncology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 210. Asia Immuno-oncology Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 211. Asia Immuno-oncology Drugs Revenue by Region (US$ Million) & (2021-2026) Table 212. Asia Immuno-oncology Drugs Revenue by Region (US$ Million) & (2027-2032) Table 213. SAMEA Immuno-oncology Drugs Revenue by Type (2021-2026) & (US$ Million) Table 214. SAMEA Immuno-oncology Drugs Revenue by Type (2027-2032) & (US$ Million) Table 215. SAMEA Immuno-oncology Drugs Revenue by Application (2021-2026) & (US$ Million) Table 216. SAMEA Immuno-oncology Drugs Revenue by Application (2027-2032) & (US$ Million) Table 217. SAMEA Immuno-oncology Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 218. SAMEA Immuno-oncology Drugs Revenue by Country (2021-2026) & (US$ Million) Table 219. SAMEA Immuno-oncology Drugs Revenue by Country (US$ Million) & (2027-2032) Table 220. Research Programs/Design for This Report Table 221. Authors List of This Report Table 222. Secondary Sources Table 223. Primary Sources List of Figures Figure 1. Immuno-oncology Drugs Image Figure 2. Global Immuno-oncology Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immuno-oncology Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oncolytic Virus Image Figure 5. Immune System Modulators Image Figure 6. Immune Checkpoint Inhibitors Image Figure 7. Cancer Vaccines Image Figure 8. Others Image Figure 9. Global Immuno-oncology Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Immuno-oncology Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 11. Clinics Image Figure 12. Hospitals Image Figure 13. Community Centers Image Figure 14. Global Immuno-oncology Drugs Market Size (US$ Million) & (2021-2032) Figure 15. Global Immuno-oncology Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Immuno-oncology Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Immuno-oncology Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Immuno-oncology Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Immuno-oncology Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Immuno-oncology Drugs Revenue Market Share by Type (2021-2032) Figure 22. Global Immuno-oncology Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Immuno-oncology Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Immuno-oncology Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Immuno-oncology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Immuno-oncology Drugs Revenue Share by Type (2021-2032) Figure 27. North America Immuno-oncology Drugs Revenue Share by Application (2021-2032) Figure 28. North America Immuno-oncology Drugs Revenue Share by Country (2021-2032) Figure 29. United States Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Immuno-oncology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Immuno-oncology Drugs Revenue Share by Type (2021-2032) Figure 34. Europe Immuno-oncology Drugs Revenue Share by Application (2021-2032) Figure 35. Europe Immuno-oncology Drugs Revenue Share by Country (2021-2032) Figure 36. Germany Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Immuno-oncology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Immuno-oncology Drugs Revenue Share by Type (2021-2032) Figure 46. China Immuno-oncology Drugs Revenue Share by Application (2021-2032) Figure 47. Asia Immuno-oncology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Immuno-oncology Drugs Revenue Share by Type (2021-2032) Figure 49. Asia Immuno-oncology Drugs Revenue Share by Application (2021-2032) Figure 50. Asia Immuno-oncology Drugs Revenue Share by Region (2021-2032) Figure 51. Japan Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Immuno-oncology Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Immuno-oncology Drugs Revenue Share by Type (2021-2032) Figure 59. SAMEA Immuno-oncology Drugs Revenue Share by Application (2021-2032) Figure 60. SAMEA Immuno-oncology Drugs Revenue Share by Country (2021-2032) Figure 61. Brazil Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Immuno-oncology Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Oncolytic Virus
  • Immune System Modulators
  • Immune Checkpoint Inhibitors
  • Cancer Vaccines
  • Others
Applications
  • Clinics
  • Hospitals
  • Community Centers
Companies covered
  • Sanofi S.A.
  • Johnson & Johnson
  • Merck & Co.
  • Lonza Group
  • Eli Lilly and Company
  • Pfizer Inc.
  • Ferring Pharmaceuticals
  • Amgen, Inc
  • AbbVie, Inc.
  • AstraZeneca, Plc
  • Spring Bank Pharmaceuticals, Inc.
  • Prometheus Therapeutics & Diagnostics
  • Novartis International AG
  • Incyte
  • ImmunoCellular Therapeutics
  • Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • Galena Biopharma
  • Enzo Biochem, Inc.
  • EMD Serono, Inc.
  • Dendreon Corporation
  • Celldex Therapeutics
  • Celgene Corporation
  • Bristol-Myers Squibb
  • Bio-Rad Laboratories, Inc.
  • Bavarian Nordic
  • Avantor, Inc.
  • Agilent Technologies Inc.
  • Agenus Inc.
  • Aduro BioTech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Immuno-oncology Drugs Market by Type
  3. 1.2.1 Global Immuno-oncology Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oncolytic Virus
  5. 1.2.3 Immune System Modulators
  6. 1.2.4 Immune Checkpoint Inhibitors
  7. 1.2.5 Cancer Vaccines
  8. 1.2.6 Others
  9. 1.3 Immuno-oncology Drugs Market by Application
  10. 1.3.1 Global Immuno-oncology Drugs Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Clinics
  12. 1.3.3 Hospitals
  13. 1.3.4 Community Centers
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Immuno-oncology Drugs Market Dynamics
  1. 2.1 Immuno-oncology Drugs Industry Trends
  2. 2.2 Immuno-oncology Drugs Industry Drivers
  3. 2.3 Immuno-oncology Drugs Industry Opportunities and Challenges
  4. 2.4 Immuno-oncology Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Immuno-oncology Drugs Market Perspective (2021-2032)
  2. 3.2 Global Immuno-oncology Drugs Growth Trends by Region
  3. 3.2.1 Global Immuno-oncology Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Immuno-oncology Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Immuno-oncology Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Immuno-oncology Drugs Revenue by Players
  2. 4.1.1 Global Immuno-oncology Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Immuno-oncology Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Immuno-oncology Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Immuno-oncology Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Immuno-oncology Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Immuno-oncology Drugs Players, Product Type & Application
  8. 4.5 Global Immuno-oncology Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Immuno-oncology Drugs Market CR5 and HHI
  11. 4.6.3 2025 Immuno-oncology Drugs Tier 1, Tier 2, and Tier 3
5 Immuno-oncology Drugs Market Size by Type
  1. 5.1 Global Immuno-oncology Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Immuno-oncology Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Immuno-oncology Drugs Revenue Market Share by Type (2021-2032)
6 Immuno-oncology Drugs Market Size by Application
  1. 6.1 Global Immuno-oncology Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Immuno-oncology Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Immuno-oncology Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi S.A.
  2. 7.1.1 Sanofi S.A. Company Information
  3. 7.1.2 Sanofi S.A. Business Overview
  4. 7.1.3 Sanofi S.A. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi S.A. Immuno-oncology Drugs Product Portfolio
  6. 7.1.5 Sanofi S.A. Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Immuno-oncology Drugs Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Merck & Co.
  14. 7.3.1 Merck & Co. Company Information
  15. 7.3.2 Merck & Co. Business Overview
  16. 7.3.3 Merck & Co. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co. Immuno-oncology Drugs Product Portfolio
  18. 7.3.5 Merck & Co. Recent Developments
  19. 7.4 Lonza Group
  20. 7.4.1 Lonza Group Company Information
  21. 7.4.2 Lonza Group Business Overview
  22. 7.4.3 Lonza Group Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Lonza Group Immuno-oncology Drugs Product Portfolio
  24. 7.4.5 Lonza Group Recent Developments
  25. 7.5 Eli Lilly and Company
  26. 7.5.1 Eli Lilly and Company Company Information
  27. 7.5.2 Eli Lilly and Company Business Overview
  28. 7.5.3 Eli Lilly and Company Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Eli Lilly and Company Immuno-oncology Drugs Product Portfolio
  30. 7.5.5 Eli Lilly and Company Recent Developments
  31. 7.6 Pfizer Inc.
  32. 7.6.1 Pfizer Inc. Company Information
  33. 7.6.2 Pfizer Inc. Business Overview
  34. 7.6.3 Pfizer Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Inc. Immuno-oncology Drugs Product Portfolio
  36. 7.6.5 Pfizer Inc. Recent Developments
  37. 7.7 Ferring Pharmaceuticals
  38. 7.7.1 Ferring Pharmaceuticals Company Information
  39. 7.7.2 Ferring Pharmaceuticals Business Overview
  40. 7.7.3 Ferring Pharmaceuticals Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolio
  42. 7.7.5 Ferring Pharmaceuticals Recent Developments
  43. 7.8 Amgen, Inc
  44. 7.8.1 Amgen, Inc Company Information
  45. 7.8.2 Amgen, Inc Business Overview
  46. 7.8.3 Amgen, Inc Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Amgen, Inc Immuno-oncology Drugs Product Portfolio
  48. 7.8.5 Amgen, Inc Recent Developments
  49. 7.9 AbbVie, Inc.
  50. 7.9.1 AbbVie, Inc. Company Information
  51. 7.9.2 AbbVie, Inc. Business Overview
  52. 7.9.3 AbbVie, Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 AbbVie, Inc. Immuno-oncology Drugs Product Portfolio
  54. 7.9.5 AbbVie, Inc. Recent Developments
  55. 7.10 AstraZeneca, Plc
  56. 7.10.1 AstraZeneca, Plc Company Information
  57. 7.10.2 AstraZeneca, Plc Business Overview
  58. 7.10.3 AstraZeneca, Plc Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio
  60. 7.10.5 AstraZeneca, Plc Recent Developments
  61. 7.11 Spring Bank Pharmaceuticals, Inc.
  62. 7.11.1 Spring Bank Pharmaceuticals, Inc. Company Information
  63. 7.11.2 Spring Bank Pharmaceuticals, Inc. Business Overview
  64. 7.11.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolio
  66. 7.11.5 Spring Bank Pharmaceuticals, Inc. Recent Developments
  67. 7.12 Prometheus Therapeutics & Diagnostics
  68. 7.12.1 Prometheus Therapeutics & Diagnostics Company Information
  69. 7.12.2 Prometheus Therapeutics & Diagnostics Business Overview
  70. 7.12.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio
  72. 7.12.5 Prometheus Therapeutics & Diagnostics Recent Developments
  73. 7.13 Novartis International AG
  74. 7.13.1 Novartis International AG Company Information
  75. 7.13.2 Novartis International AG Business Overview
  76. 7.13.3 Novartis International AG Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Novartis International AG Immuno-oncology Drugs Product Portfolio
  78. 7.13.5 Novartis International AG Recent Developments
  79. 7.14 Incyte
  80. 7.14.1 Incyte Company Information
  81. 7.14.2 Incyte Business Overview
  82. 7.14.3 Incyte Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Incyte Immuno-oncology Drugs Product Portfolio
  84. 7.14.5 Incyte Recent Developments
  85. 7.15 ImmunoCellular Therapeutics
  86. 7.15.1 ImmunoCellular Therapeutics Company Information
  87. 7.15.2 ImmunoCellular Therapeutics Business Overview
  88. 7.15.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio
  90. 7.15.5 ImmunoCellular Therapeutics Recent Developments
  91. 7.16 Hoffmann-La Roche AG
  92. 7.16.1 Hoffmann-La Roche AG Company Information
  93. 7.16.2 Hoffmann-La Roche AG Business Overview
  94. 7.16.3 Hoffmann-La Roche AG Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio
  96. 7.16.5 Hoffmann-La Roche AG Recent Developments
  97. 7.17 Gilead Sciences Inc.
  98. 7.17.1 Gilead Sciences Inc. Company Information
  99. 7.17.2 Gilead Sciences Inc. Business Overview
  100. 7.17.3 Gilead Sciences Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolio
  102. 7.17.5 Gilead Sciences Inc. Recent Developments
  103. 7.18 Galena Biopharma
  104. 7.18.1 Galena Biopharma Company Information
  105. 7.18.2 Galena Biopharma Business Overview
  106. 7.18.3 Galena Biopharma Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Galena Biopharma Immuno-oncology Drugs Product Portfolio
  108. 7.18.5 Galena Biopharma Recent Developments
  109. 7.19 Enzo Biochem, Inc.
  110. 7.19.1 Enzo Biochem, Inc. Company Information
  111. 7.19.2 Enzo Biochem, Inc. Business Overview
  112. 7.19.3 Enzo Biochem, Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolio
  114. 7.19.5 Enzo Biochem, Inc. Recent Developments
  115. 7.20 EMD Serono, Inc.
  116. 7.20.1 EMD Serono, Inc. Company Information
  117. 7.20.2 EMD Serono, Inc. Business Overview
  118. 7.20.3 EMD Serono, Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  119. 7.20.4 EMD Serono, Inc. Immuno-oncology Drugs Product Portfolio
  120. 7.20.5 EMD Serono, Inc. Recent Developments
  121. 7.21 Dendreon Corporation
  122. 7.21.1 Dendreon Corporation Company Information
  123. 7.21.2 Dendreon Corporation Business Overview
  124. 7.21.3 Dendreon Corporation Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Dendreon Corporation Immuno-oncology Drugs Product Portfolio
  126. 7.21.5 Dendreon Corporation Recent Developments
  127. 7.22 Celldex Therapeutics
  128. 7.22.1 Celldex Therapeutics Company Information
  129. 7.22.2 Celldex Therapeutics Business Overview
  130. 7.22.3 Celldex Therapeutics Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Celldex Therapeutics Immuno-oncology Drugs Product Portfolio
  132. 7.22.5 Celldex Therapeutics Recent Developments
  133. 7.23 Celgene Corporation
  134. 7.23.1 Celgene Corporation Company Information
  135. 7.23.2 Celgene Corporation Business Overview
  136. 7.23.3 Celgene Corporation Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Celgene Corporation Immuno-oncology Drugs Product Portfolio
  138. 7.23.5 Celgene Corporation Recent Developments
  139. 7.24 Bristol-Myers Squibb
  140. 7.24.1 Bristol-Myers Squibb Company Information
  141. 7.24.2 Bristol-Myers Squibb Business Overview
  142. 7.24.3 Bristol-Myers Squibb Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  143. 7.24.4 Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio
  144. 7.24.5 Bristol-Myers Squibb Recent Developments
  145. 7.25 Bio-Rad Laboratories, Inc.
  146. 7.25.1 Bio-Rad Laboratories, Inc. Company Information
  147. 7.25.2 Bio-Rad Laboratories, Inc. Business Overview
  148. 7.25.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  149. 7.25.4 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolio
  150. 7.25.5 Bio-Rad Laboratories, Inc. Recent Developments
  151. 7.26 Bavarian Nordic
  152. 7.26.1 Bavarian Nordic Company Information
  153. 7.26.2 Bavarian Nordic Business Overview
  154. 7.26.3 Bavarian Nordic Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  155. 7.26.4 Bavarian Nordic Immuno-oncology Drugs Product Portfolio
  156. 7.26.5 Bavarian Nordic Recent Developments
  157. 7.27 Avantor, Inc.
  158. 7.27.1 Avantor, Inc. Company Information
  159. 7.27.2 Avantor, Inc. Business Overview
  160. 7.27.3 Avantor, Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  161. 7.27.4 Avantor, Inc. Immuno-oncology Drugs Product Portfolio
  162. 7.27.5 Avantor, Inc. Recent Developments
  163. 7.28 Agilent Technologies Inc.
  164. 7.28.1 Agilent Technologies Inc. Company Information
  165. 7.28.2 Agilent Technologies Inc. Business Overview
  166. 7.28.3 Agilent Technologies Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  167. 7.28.4 Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolio
  168. 7.28.5 Agilent Technologies Inc. Recent Developments
  169. 7.29 Agenus Inc.
  170. 7.29.1 Agenus Inc. Company Information
  171. 7.29.2 Agenus Inc. Business Overview
  172. 7.29.3 Agenus Inc. Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  173. 7.29.4 Agenus Inc. Immuno-oncology Drugs Product Portfolio
  174. 7.29.5 Agenus Inc. Recent Developments
  175. 7.30 Aduro BioTech
  176. 7.30.1 Aduro BioTech Company Information
  177. 7.30.2 Aduro BioTech Business Overview
  178. 7.30.3 Aduro BioTech Immuno-oncology Drugs Revenue and Gross Margin (2021-2026)
  179. 7.30.4 Aduro BioTech Immuno-oncology Drugs Product Portfolio
  180. 7.30.5 Aduro BioTech Recent Developments
8 North America
  1. 8.1 North America Immuno-oncology Drugs Revenue (2021-2032)
  2. 8.2 North America Immuno-oncology Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Immuno-oncology Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Immuno-oncology Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Immuno-oncology Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Immuno-oncology Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Immuno-oncology Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Immuno-oncology Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Immuno-oncology Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Immuno-oncology Drugs Revenue by Country
  11. 8.6.1 North America Immuno-oncology Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Immuno-oncology Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Immuno-oncology Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Immuno-oncology Drugs Revenue (2021-2032)
  2. 9.2 Europe Immuno-oncology Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Immuno-oncology Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Immuno-oncology Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Immuno-oncology Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Immuno-oncology Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Immuno-oncology Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Immuno-oncology Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Immuno-oncology Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Immuno-oncology Drugs Revenue by Country
  11. 9.6.1 Europe Immuno-oncology Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Immuno-oncology Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Immuno-oncology Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Immuno-oncology Drugs Revenue (2021-2032)
  2. 10.2 China Immuno-oncology Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Immuno-oncology Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Immuno-oncology Drugs Revenue by Type (2027-2032)
  5. 10.3 China Immuno-oncology Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Immuno-oncology Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Immuno-oncology Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Immuno-oncology Drugs Revenue by Application (2027-2032)
  9. 10.5 China Immuno-oncology Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Immuno-oncology Drugs Revenue (2021-2032)
  2. 11.2 Asia Immuno-oncology Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Immuno-oncology Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Immuno-oncology Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Immuno-oncology Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Immuno-oncology Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Immuno-oncology Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Immuno-oncology Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Immuno-oncology Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Immuno-oncology Drugs Revenue by Country
  11. 11.6.1 Asia Immuno-oncology Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Immuno-oncology Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Immuno-oncology Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Immuno-oncology Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Immuno-oncology Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Immuno-oncology Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Immuno-oncology Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Immuno-oncology Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Immuno-oncology Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Immuno-oncology Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Immuno-oncology Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Immuno-oncology Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Immuno-oncology Drugs Revenue by Country
  11. 12.6.1 SAMEA Immuno-oncology Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Immuno-oncology Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Immuno-oncology Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst